Asset Details
Do you wish to reserve the book?
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
Do you wish to request the book?
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
2018
Overview
Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival in patients with mCRC. Panitumumab is used in different lines of therapy in combination with chemotherapy, and as monotherapy for the treatment of wild-type (WT)
RAS
mCRC. It is administered as an intravenous infusion of 6 mg/kg every 2 weeks and has a
t
½
of approximately 7.5 days. Elimination takes place via two different mechanisms, and immunogenicity rates are low. Only
RAS
mutations have been confirmed as a negative predictor of efficacy with anti-EGFR antibodies. Panitumumab is generally well tolerated and has a manageable toxicity profile, despite a very high prevalence of dermatologic side effects. This article presents an overview of the clinical pharmacokinetics and pharmacodynamics of panitumumab, including a description of the studies that led to its approval in the different lines of therapy of mCRC.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Antineoplastic Agents, Immunological - administration & dosage
/ Antineoplastic Agents, Immunological - adverse effects
/ Antineoplastic Agents, Immunological - pharmacokinetics
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - enzymology
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - pathology
/ Drug Administration Schedule
/ ErbB Receptors - antagonists & inhibitors
/ Humans
/ Kinases
/ Ligands
/ Medicine
/ Mutation
/ Panitumumab - administration & dosage
/ Panitumumab - adverse effects
/ Panitumumab - pharmacokinetics
/ Review
/ Studies
